CLINICAL TRIALS PROFILE FOR LIPIDIL
✉ Email this page to a colleague
All Clinical Trials for LIPIDIL
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00458055 ↗ | High-Density Lipoprotein (HDL) Treatment Study | Completed | McGill University Health Center | N/A | 2006-11-01 | A low level of plasma high-density lipoprotein (HDL) cholesterol, "the good cholesterol", is the most common lipid abnormality observed in patients with a premature atherosclerotic cardiovascular disease. HDL carry excess cholesterol from peripheral tissues to the liver to be metabolized or excreted, a process known as reverse cholesterol transport. Epidemiological studies have shown an inverse correlation between plasma levels of HDL cholesterol and the risk of cardiovascular disease. An increase in plasma HDL cholesterol levels by 1 mg/dL may reduce the risk of cardiovascular disease by 2 to 3%. The standard care of treatment for a low level of HDL cholesterol is: 1) lifestyle modifications including exercise, smoking cessation, weight control, moderate alcohol intake and decreased dietary fat intake - all patients are encouraged to follow these lifestyle modifications; 2) medications which can raise HDL cholesterol. Currently used medications to treat lipid disorders can increase, in some extent, HDL cholesterol. These include niacin (vitamin B3), fibric acid derivatives (fibrates) and statins. However there is no data on the effect of these medications on severe cases of HDL deficiency. This project aims to determine whether currently available medications, used in standard medical practice for the treatment of lipoprotein disorders, can substantially increase HDL cholesterol in severe cases of HDL deficiencies. |
| NCT00458055 ↗ | High-Density Lipoprotein (HDL) Treatment Study | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | N/A | 2006-11-01 | A low level of plasma high-density lipoprotein (HDL) cholesterol, "the good cholesterol", is the most common lipid abnormality observed in patients with a premature atherosclerotic cardiovascular disease. HDL carry excess cholesterol from peripheral tissues to the liver to be metabolized or excreted, a process known as reverse cholesterol transport. Epidemiological studies have shown an inverse correlation between plasma levels of HDL cholesterol and the risk of cardiovascular disease. An increase in plasma HDL cholesterol levels by 1 mg/dL may reduce the risk of cardiovascular disease by 2 to 3%. The standard care of treatment for a low level of HDL cholesterol is: 1) lifestyle modifications including exercise, smoking cessation, weight control, moderate alcohol intake and decreased dietary fat intake - all patients are encouraged to follow these lifestyle modifications; 2) medications which can raise HDL cholesterol. Currently used medications to treat lipid disorders can increase, in some extent, HDL cholesterol. These include niacin (vitamin B3), fibric acid derivatives (fibrates) and statins. However there is no data on the effect of these medications on severe cases of HDL deficiency. This project aims to determine whether currently available medications, used in standard medical practice for the treatment of lipoprotein disorders, can substantially increase HDL cholesterol in severe cases of HDL deficiencies. |
| NCT00809068 ↗ | High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone | Completed | Keogh Institute for Medical Research | Phase 4 | 2005-08-01 | Tibolone (Livial) has been shown in previous studies to lower HDL cholesterol by up to 40%. This study aims to study the effects of fenofibrate on HDL and subfractions in women taking tibolone. |
| NCT01353404 ↗ | Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg) | Completed | Samyang Biopharmaceuticals Corporation | Phase 1 | 2011-06-01 | The purpose of this study is to evaluate the bioequivalence of Lipidil® Supra (fenofibrate 160mg) versus SYO-0805 (fenofibrate 65mg) in single dose oral administration. |
| NCT01501435 ↗ | To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra | Completed | CJ HealthCare Corporation | Phase 1 | 2011-12-01 | To investigate the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra |
| NCT01501435 ↗ | To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra | Completed | HK inno.N Corporation | Phase 1 | 2011-12-01 | To investigate the safety and pharmacokinetic properties of CJ-30039 and Lipidil Supra |
| NCT02651753 ↗ | A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 | Completed | Chong Kun Dang Pharmaceutical | Phase 1 | 2016-01-01 | This study is a randomized, open-label, single oral dose, 2-way crossover clinical trial to compare safety and pharmacokinetics of CKD-337 in healthy male volunteers. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LIPIDIL
Condition Name
Clinical Trial Locations for LIPIDIL
Clinical Trial Progress for LIPIDIL
Clinical Trial Phase
Clinical Trial Sponsors for LIPIDIL
Sponsor Name
